Nuclea Biotechnologies - Creating A New Standard For Cancer Diagnostics

Medical Imaging & Radiological
Diagnostics

Drug Response Assays

Lymphoproliferative Disease

Cardiac Serum Diagnostics

.............................................................

February 2nd, 2012
Nuclea Biotechnologies Announces $3.4 Million in Capital Commitments

.............................................................

January 11th, 2012
Nuclea Biotechnologies Submits Pre-Market Filings on Fatty Acid Synthase Assays for FDA Regulatory Review

Please log in to access Nuclea Biotechnologies Client Site.